DE69718924D1 - FUSOGENIC LIPOSOME COMPOSITION AND METHOD - Google Patents

FUSOGENIC LIPOSOME COMPOSITION AND METHOD

Info

Publication number
DE69718924D1
DE69718924D1 DE69718924T DE69718924T DE69718924D1 DE 69718924 D1 DE69718924 D1 DE 69718924D1 DE 69718924 T DE69718924 T DE 69718924T DE 69718924 T DE69718924 T DE 69718924T DE 69718924 D1 DE69718924 D1 DE 69718924D1
Authority
DE
Germany
Prior art keywords
liposome
composition
target cells
hydrophobic polymers
liposome composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69718924T
Other languages
German (de)
Other versions
DE69718924T2 (en
Inventor
J Martin
Samuel Zalipsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Sequus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharmaceuticals Inc filed Critical Sequus Pharmaceuticals Inc
Publication of DE69718924D1 publication Critical patent/DE69718924D1/en
Application granted granted Critical
Publication of DE69718924T2 publication Critical patent/DE69718924T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Abstract

A fusogenic liposome composition for delivering a liposome-entrapped compound into the cytoplasm of a target cell is described. The liposomes have an outer surface coating of chemically releasable hydrophilic polymer chains which shield hydrophobic polymers on the liposome outer surface. Release of the hydrophilic polymer chains exposes the hydrophobic polymers for interaction with outer cell membranes of the target cells to promote fusion of the liposome with the target cells. Also disclosed is a method for using the composition to deliver a compound to target cells, and a method for selecting suitable hydrophobic polymers for use in the composition.
DE69718924T 1996-10-11 1997-10-10 FUSOGENIC LIPOSOME COMPOSITION AND METHOD Expired - Fee Related DE69718924T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2826996P 1996-10-11 1996-10-11
PCT/US1997/018838 WO1998016202A2 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method

Publications (2)

Publication Number Publication Date
DE69718924D1 true DE69718924D1 (en) 2003-03-13
DE69718924T2 DE69718924T2 (en) 2003-12-04

Family

ID=21842486

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69718924T Expired - Fee Related DE69718924T2 (en) 1996-10-11 1997-10-10 FUSOGENIC LIPOSOME COMPOSITION AND METHOD

Country Status (15)

Country Link
US (1) US5891468A (en)
EP (1) EP0932391B1 (en)
JP (1) JP2001504093A (en)
AT (1) ATE232086T1 (en)
AU (1) AU715063B2 (en)
BR (1) BR9712230A (en)
CA (1) CA2267904C (en)
DE (1) DE69718924T2 (en)
DK (1) DK0932391T3 (en)
ES (1) ES2191833T3 (en)
HK (1) HK1047550A1 (en)
IL (1) IL129292A0 (en)
PT (1) PT932391E (en)
TW (1) TW520297B (en)
WO (1) WO1998016202A2 (en)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
AU729655B2 (en) * 1996-11-12 2001-02-08 Regents Of The University Of California, The Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6936729B2 (en) * 1998-05-16 2005-08-30 Mirus Bio Corporation Compound containing a labile disulfide bond
US7087770B2 (en) 1998-05-16 2006-08-08 Mirus Bio Corporation Compound containing a labile disulfide bond
EP1121102B1 (en) * 1998-09-16 2003-04-23 Alza Corporation Liposome-entrapped topoisomerase inhibitors
CA2353593A1 (en) * 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
JP5117648B2 (en) * 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Cationic PEG lipids and methods of use.
KR100642955B1 (en) * 1999-04-23 2006-11-10 알자 코포레이션 Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
IL146047A0 (en) * 1999-04-23 2002-07-25 Alza Corp Releasable linkage and compositions containing same
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
EP1180242A1 (en) * 1999-05-27 2002-02-20 Zeptosens AG Vesicle containing polymers and sensor detection methods based thereon
CZ2002140A3 (en) * 1999-07-14 2002-05-15 Alza Corporation Neutral lipopolymer and liposome compositions containing thereof
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6916488B1 (en) * 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
CA2391606A1 (en) * 1999-11-24 2001-05-31 The Liposome Company, Inc. Modular targeted liposomal delivery system
US20030147944A1 (en) * 1999-12-10 2003-08-07 Mayer Lawrence D Lipid carrier compositions with protected surface reactive functions
MXPA02007320A (en) * 2000-01-28 2004-07-30 Alza Corp Liposomes containing an entrapped compound in supersaturated solution.
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
WO2001080900A2 (en) * 2000-04-20 2001-11-01 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
KR100784120B1 (en) 2000-06-02 2007-12-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 EthylenedicysteineEC-drug conjugates
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1341497A4 (en) * 2000-11-02 2005-10-19 Smithkline Beecham Corp Receptor antagonist-lipid conjugates and delivery vehicles containing same
US6613280B2 (en) 2001-03-20 2003-09-02 Therox, Inc. Disposable cartridge for producing gas-enriched fluids
AU2002306821A1 (en) * 2001-03-22 2002-10-08 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
JP2004525138A (en) * 2001-03-26 2004-08-19 アルザ・コーポレーシヨン Liposomal compositions for improved intracellular delivery of therapeutic agents
WO2002088318A2 (en) * 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP1572067A4 (en) * 2001-05-18 2009-05-13 Sirna Therapeutics Inc Conjugates and compositions for cellular delivery
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2003072091A1 (en) * 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
WO2003083443A2 (en) * 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
WO2004007662A2 (en) * 2002-04-23 2004-01-22 The Research Foundation Of State University Of New York Polymer surfactants for gene therapy applications
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (en) * 2002-06-03 2003-06-09 メビオファーム株式会社 Liposome preparation
US20040093198A1 (en) * 2002-11-08 2004-05-13 Carbon Design Systems Hardware simulation with access restrictions
KR101177340B1 (en) † 2003-01-06 2012-08-30 넥타르 테라퓨틱스 Thiol-selective water-soluble polymer derivatives
JPWO2004063216A1 (en) * 2003-01-10 2006-06-15 アステラス製薬株式会社 Conjugates for blood retention and cancer tissue specific drug delivery
WO2004078121A2 (en) * 2003-02-28 2004-09-16 Alza Coporation Liposome composition for reduction of liposome-induced complement activation
CA2520864A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
CA2527625A1 (en) * 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
US8846079B1 (en) * 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
AU2004267875B2 (en) * 2003-08-29 2010-09-02 Newcastle Innovation Limited Stimulant sensitive flocculation and consolidation
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
JP2007533647A (en) * 2003-10-24 2007-11-22 アルザ・コーポレーシヨン Preparation of lipid particles
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
KR20060103957A (en) * 2004-01-15 2006-10-04 알자 코포레이션 Liposome composition for delivery of therapeutic agents
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
EP1809246B1 (en) * 2004-10-08 2008-07-16 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
WO2006088245A1 (en) * 2005-02-18 2006-08-24 The University Of Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
KR20080042045A (en) * 2005-05-23 2008-05-14 에스디지,인코포레이티드 Lipid construct for delivery of interferon to a mammal
WO2007008300A2 (en) 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
ES2594368T3 (en) 2005-12-08 2016-12-19 Insmed Incorporated Lipid-based compositions of anti-infectives to treat lung infections
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
CA2654302A1 (en) 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
US20080031883A1 (en) * 2006-07-13 2008-02-07 Torchilin Vladimir P Condition-dependent, multiple target delivery system
US8343539B2 (en) * 2006-07-14 2013-01-01 Regents Of The University Of Minnesota Compounds that bind α5β1 integrin and methods of use
US8071082B2 (en) 2006-07-21 2011-12-06 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
MX2009003092A (en) * 2006-09-22 2009-05-08 Labopharm Inc Compositions and methods for ph targeted drug delivery.
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US20100210575A1 (en) * 2007-06-29 2010-08-19 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
WO2009154688A1 (en) * 2008-05-28 2009-12-23 President And Fellows Of Harvard College A pre-fabricated electron microscopy grid for monolayer purification and methods and kits therefor
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102149749B (en) * 2008-07-10 2014-06-25 塞瑞纳治疗公司 Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
EP2365962B1 (en) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalcohol lipidoids and uses thereof
JP5814793B2 (en) 2008-11-25 2015-11-17 エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） Block copolymer and use thereof
AR074977A1 (en) 2008-12-23 2011-03-02 Pharmasset Inc SYNTHESIS OF PURINE NUCLEOSIDS
PT2376088T (en) 2008-12-23 2017-05-02 Gilead Pharmasset Llc 6-o-substituted-2-amino-purine nucleoside phosphoramidates
CN102753563A (en) 2008-12-23 2012-10-24 吉利德制药有限责任公司 Nucleoside analogs
EP2230515B1 (en) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivation of surfaces after ligand coupling
SG10201402054UA (en) * 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
PT2474306T (en) 2009-08-31 2016-12-07 Nanocarrier Co Ltd Particle composition and medicinal composition comprising same
PT2506857T (en) 2009-12-01 2018-05-14 Translate Bio Inc Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
JP4829351B2 (en) 2010-02-05 2011-12-07 ナノキャリア株式会社 Easily disintegrating polymer micelle composition
CN102858790A (en) 2010-03-31 2013-01-02 吉利德制药有限责任公司 Nucleoside Phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011160110A1 (en) 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
TW201242974A (en) 2010-11-30 2012-11-01 Gilead Pharmasset Llc Compounds
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
AU2012254842A1 (en) * 2011-05-12 2013-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
SI2717893T1 (en) 2011-06-08 2019-10-30 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
EA032088B1 (en) 2011-10-27 2019-04-30 Массачусетс Инститьют Оф Текнолоджи Amino acid derivates functionalized on the n-terminal capable of forming drug incapsulating microspheres
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
AU2013292636A1 (en) 2012-07-18 2015-02-05 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
CN102920658B (en) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 Liposome combined with GLP-1 (Glucagon-Like Peptide-1) analogue and polyethylene glycol and preparation method of liposome
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
CA2903255C (en) * 2013-03-13 2018-08-28 Mallinckrodt Llc Modified docetaxel liposome formulations
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
KR102311614B1 (en) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna compositions and related methods and uses
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
CA2928078A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
CN105658242A (en) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 MRNA therapy for phenylketonuria
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MX2016009771A (en) 2014-01-31 2016-11-14 Factor Bioscience Inc Methods and products for nucleic acid production and delivery.
MA39819A (en) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Methods and compositions for immunomodulation
CN110511927A (en) 2014-04-25 2019-11-29 川斯勒佰尔公司 The purification process of mRNA
PT3142643T (en) 2014-05-15 2019-10-28 Insmed Inc Methods for treating pulmonary non-tuberculous mycobacterial infections
JP6557722B2 (en) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Biodegradable lipids for delivery of nucleic acids
CN111588695A (en) 2014-06-24 2020-08-28 川斯勒佰尔公司 Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN104546722B (en) * 2015-02-10 2017-05-24 中国医学科学院医药生物技术研究所 Miriplatin lipidosome and preparation method thereof
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990172A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
JP6894423B2 (en) 2015-07-09 2021-06-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ Fusible liposome-coated porous silicon nanoparticles
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
MA47603A (en) 2017-02-27 2020-01-01 Translate Bio Inc NEW ARNM CFTR WITH OPTIMIZED CODONS
EP3595636A4 (en) 2017-03-16 2021-01-13 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
BR112019022016A2 (en) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE OF THE SAME IN CANCER TREATMENT
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3700965A1 (en) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly (beta-amino esters) and uses thereof
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN112930396A (en) 2018-08-24 2021-06-08 川斯勒佰尔公司 Method for purifying messenger RNA
CA3117914A1 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
EP3870629A1 (en) 2018-10-26 2021-09-01 Massachusetts Institute of Technology Polymer-lipids and compositions
WO2023210671A1 (en) * 2022-04-26 2023-11-02 京セラ株式会社 Copolymer, polymer film, measuring device, and support for measurement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136095A (en) * 1987-05-19 1992-08-04 Syntex (U.S.A.) Inc. Reversible agglutination mediators
JPH0720857B2 (en) * 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3220180B2 (en) * 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes
JPH07173079A (en) * 1992-12-22 1995-07-11 Nippon Oil & Fats Co Ltd Amphiphatic polyethylene glycol derivative and its use
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes

Also Published As

Publication number Publication date
PT932391E (en) 2003-06-30
ATE232086T1 (en) 2003-02-15
AU715063B2 (en) 2000-01-13
JP2001504093A (en) 2001-03-27
CA2267904A1 (en) 1998-04-23
TW520297B (en) 2003-02-11
AU4987897A (en) 1998-05-11
DK0932391T3 (en) 2003-05-26
EP0932391A2 (en) 1999-08-04
WO1998016202A3 (en) 1998-07-16
DE69718924T2 (en) 2003-12-04
HK1047550A1 (en) 2003-02-28
EP0932391B1 (en) 2003-02-05
IL129292A0 (en) 2000-02-17
US5891468A (en) 1999-04-06
BR9712230A (en) 2000-01-25
CA2267904C (en) 2005-08-02
WO1998016202A2 (en) 1998-04-23
ES2191833T3 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
DE69718924D1 (en) FUSOGENIC LIPOSOME COMPOSITION AND METHOD
MY122195A (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
DK0929293T3 (en) Liposomes containing a cisplatin compound
ES555277A0 (en) PROCEDURE FOR OBTAINING A GRAFTING COMPOSITION FOR THE CONTROLLED RELEASE OF MACROMOLECULES
AU1742597A (en) A hydrophilic, graphite fuel cell electrode for use with an ionomer membrane and method of making a fuel cell
MXPA02004574A (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it.
DE69710787D1 (en) COMPOSITE CATHODES, ELECTROCHEMICAL CELLS WITH COMPOSITE CATHODES AND METHOD FOR THE PRODUCTION THEREOF
AU1406897A (en) New polymer material for electrolytic membranes in fuel cells
WO2001057940A3 (en) Freestanding microporous separator including a gel-forming polymer
EP0875524A3 (en) Composite membranes
DE69834177D1 (en) BIOZIDES POWDER WITH DELAYED RELEASE
AU6266398A (en) Method of preparing electrochemical cells
WO1999033500A3 (en) Methods, systems, and kits for intravascular nucleic acid delivery
DE69838244D1 (en) NON-CIRCULAR ELECTROLYTE SECONDARY CELL AND METHOD FOR PRODUCING POSITIVE ACTIVE MATERIALS THEREFOR
DE69706592D1 (en) Process for the production of positive electrode active material, and non-aqueous secondary battery using the same
AU2124495A (en) Bipolar battery cells, batteries, and methods
DE69934064D1 (en) Polymer electrolyte and polymer, process for their preparation and battery containing them
AU6354196A (en) A wound electrochemical cell, a method for the manufacture thereof, and the use of such electrochemical cells
AU7277598A (en) Energy delivery of catheter and method for the use thereof
EP1214935A3 (en) Fusogenic liposome composition and method
AU673414B2 (en) Cathodic active material composition for dry cells, method for preparing the same, and alkaline battery
AU2275697A (en) Use of cell membrane permeants in the treatment of cellular proliferative disea ses
WO2001013446A2 (en) Material for positive electrode of lithium secondary cell and method for preparing the same
AU7489996A (en) A negative electrode composition for lithium secondary batteries, a method for the production thereof, use of said composition in lithium secondary batteries and lithium secondary batteries containing said negative electrode composition

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee